LivaNova (FRA:LIA) Current Accrued Expense: €53 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LIA LivaNova PLC FRA:LIA
76 GF Score
Price €68.00
GF Value €54.88
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is LivaNova Current Accrued Expense?

LivaNova FRA:LIA -0.73% 76 Current Accrued Expense is €53 Mil as of Jun. 2026. GuruFocus rates FRA:LIA with a GF Score™ of 76/100 and a GF Value™ of €54.88 (Modestly Overvalued). The stock has 5 warning signs investors should review.

LivaNova's Current Accrued Expense for the quarter that ended in Jun. 2026 was €53 Mil.

LivaNova's quarterly Current Accrued Expense increased from Dec. 2025 (€44 Mil) to Mar. 2026 (€51 Mil) and increased from Mar. 2026 (€51 Mil) to Jun. 2026 (€53 Mil).

LivaNova's annual Current Accrued Expense increased from Dec. 2023 (€44 Mil) to Dec. 2024 (€59 Mil) but then declined from Dec. 2024 (€59 Mil) to Dec. 2025 (€44 Mil).

LivaNova Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for LivaNova's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LivaNova Current Accrued Expense Chart

LivaNova Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.87 42.96 44.49 59.37 43.75

LivaNova Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.88 42.40 43.75 51.17 52.83
FRA:LIA
76GF Score
LivaNova PLC FRA:LIA
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LivaNova Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €53 Mil mean?
LivaNova (FRA:LIA) has a Current Accrued Expense of €53 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on LivaNova and its competitors.
Is LivaNova's Current Accrued Expense too high?
LivaNova's current Current Accrued Expense is €53 Mil. Overall, LivaNova has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's Current Accrued Expense compare to ITGR and HAE?
LivaNova's Current Accrued Expense of €53 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on LivaNova and its competitors. LivaNova's current Current Accrued Expense is €53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (FRA:LIA) is currently considered Modestly Overvalued. The stock's GF Value™ is €54.88, compared to a current price of €68.00 — trading 23.9% above its estimated fair value. The current Current Accrued Expense is €53 Mil. LivaNova's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For LivaNova (FRA:LIA), the current Current Accrued Expense is €53 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LivaNova (FRA:LIA) Overvalued in 2026?

Based on GuruFocus' analysis, LivaNova stock appears to be overvalued. The current stock price of €68.00 is trading 23.9% above its estimated GF Value™ of €54.88. GuruFocus considers LivaNova to be Modestly Overvalued.

Key valuation signals for FRA:LIA:

  • Current Accrued Expense: €53 Mil
  • GF Value™: €54.88 vs. price of €68.00 (23.9% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the FRA:LIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LivaNova Business Description

Other Exchanges LIVN:USA
Address 20 Eastbourne Terrace, London, GBR, W2 6LG
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
76GF Score

Get the complete analysis for FRA:LIA

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.00
Price
€54.88
GF Value